MAP2K7 and malignant conjunctival melanoma: The combination of Ganetespid and a MEK inhibitor, TAK-733 (also very effective in conjunctival melanoma cell lines in our study), allowed significant growth reduction in an in vivo model of BRAF resistant melanoma cell lines [88].